The study found that the use of ANP (13 trials in cardiac surgery and 1 trial in vascular surgery; 2207 patients) reduced 30-day mortality and AKI, with subgroup analyses demonstrating a significant treatment effect of ANP on AKI, mortality, and RRT in cardiac surgery cohorts [104]. This evidence concerns the gene NPPA and acute kidney injury.